论文部分内容阅读
β—受体阻滞剂因对心肌有明显的负性肌力作用,长期以来在心衰病人中视为禁忌。1975年Waagstein首先使用β—受体阻滞剂治疗7例扩张型心肌病并取得满意的疗效,此结果受到了临床心脏病学者们普遍关注。本文报道慢型克山病引起心衰18例患者,在常规使用强心、利尿、扩血管药物等方法治疗后,症状仍难以控制,经加用小剂量培他乐克治疗取得了明显疗效。现将β_1受体阻滞剂—培他乐克在心衰中的作用、机理及应用时应注意等问
Beta-blockers have been shown to be contraindicated in patients with heart failure for a long time due to their pronounced negative inotropic effects on the myocardium. 1975 Waagstein first use of β-blockers in the treatment of 7 cases of dilated cardiomyopathy and achieve satisfactory results, the results have been widespread concern of clinical cardiologists. This article reports chronic Keshan disease caused by heart failure in 18 patients, in the conventional use of cardiac, diuretic, vasodilator drugs and other methods of treatment, the symptoms are still difficult to control, with the addition of small doses of metoprolol treatment has achieved significant results. Now beta 1 receptor blocker - Pei taboca in the role of heart failure, mechanism and application should pay attention to wait